N/A
Completed N=74
An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer
Source: ClinicalTrials.gov NCT01442155 ↗Enrolled (actual)
74
Serious AEs
1.4%
Results posted
Jul 2016
Primary outcomePrimary: Disease-Free Survival (Time to Event) — 25 months
Summary
This observational study evaluates the efficacy and safety of capecitabine in combination with oxaliplatin in the adjuvant setting in participants with Stage III colon cancer. Data were collected from each participant for up to 36 months or until disease recurrence.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Disease-Free Survival (Time to Event) |
25 | — |
| SECONDARY Safety: Percentage of Participants With Adverse Events |
39.19 | — |
Eligibility Criteria
Inclusion Criteria
- Adult participants, >/= 18 years of age
- Treatment in line with the currently approved indication in the Summary of Product Characteristics
Exclusion Criteria
- Contraindications according to the current Summary of Product Characteristics
Data sourced from ClinicalTrials.gov (NCT01442155). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.